PaTu 8902 SMAD4-deficient cells, reconstituted wt SMAD4
| Inventor | Institute |
|---|---|
| Ji?? Neu?il | Institute of Biotechnology of the Academy of Sciences of the Czech Republic |
| SKU: | 161577 |
|---|---|
| Product description: | SMAD4 is an important tumor suppressor involved in transforming growth factor ? (TGF?) signaling, and associated with altered mitochondrial activity. The resistance of SMAD4-deficient cells is mediated by increased mitophagic flux driven by MAPK/ERK signaling, whereas TGF?-induced resistance is autophagy-independent and linked to epithelial-to-mesenchymal transition (EMT). Mitochondria-targeted tamoxifen, a complex I inhibitor under clinical trial, overcomes resistance mediated by SMAD4-deficiency or TGF? signaling. Our data point to differential mechanisms underlying the resistance to treatment in PDAC arising from TGF? signaling and SMAD4 loss, respectively. |
| Alternate name: | PaTu 8902 SMAD4-deficient cells, reconstituted wt SMAD4 |
| Gender: | Female |
| CRISPR: | Yes |
| Conditional: | No |
| Parental cell line: | PaTu 8902 |
| Model description: | SMAD4 knock-out cells, wild-type SMAD4 reconstituted using lentiviral transduction (pCDH-CMV vector) |
| Disease: | Cancer |
| Products or characteristics of interest: | Stable expression of SMAD4 |
| Cat. #: | 161577 |
|---|---|
| Research Fields: | Cancer |
| Organism: | Human |
| Tissue: | Pancreas |
| Gender: | Female |
| Model: | Transgeneic |
| Morphology: | Epithelial cells |
| Growth properties: | Adherent |
| Cancer Types In Detail: | Pancreatic ductal adenocarcinoma |
| Primary citation: | Ezrova et al. Oncogene. 2021 Apr, 40(14):2539-2552. PMID: 33686239 |
| Storage conditions: | Liquid Nitrogen |
|---|---|
| Shipping conditions: | Dry Ice |
| Growth medium: | DMEM+10% FBS |
| Subculture routine: | Trypsin-EDTA |
| Temperature: | 37° C |
| Atmosphere: | 5% CO2 |
| Storage medium: | Complete medium + 10% DMSO |
| Recommended controls: | PaTu 8902 SMAD4 KO |
| Mycoplasma free: | Yes |
| Biosafety level: | 1 |
| References: |
Ezrova et al. Oncogene. 2021 Apr, 40(14):2539-2552. PMID: 33686240 |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.